Tango Therapeutics, Inc.

TNGX Healthcare Biotechnology

Tango Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.4 million, up 48.3% from fiscal 2024. In the quarter to June 2026, revenue fell 100.0%, EPS fell 5.71% and free cash flow fell 4.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

22.04 0.66 −2.91%
Market cap
$3.8B
P/E
0.0×
Fwd P/E
−15.3×
Dividend yield
—
F-score
4/9
Altman Z
9.88
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
— — 4 3

+8 more TTM periods

ROE
(21.34%) (38.42%) (37.23%) (51.65%)
ROA
(18.86%) (30.20%) (28.41%) (35.74%)
ROIC
(808.35%) (629.60%) (2,661.91%) (1,015.30%)
Return on Tangible Assets
(12.16%) (27.90%) (29.97%) (65.83%)
Average Days of Receivables
— — 0.00 0.00
Free Cash Flow per Share
(0.96) (0.99) (1.20) (1.32)
Free Cash Flow
(144.25) (142.54) (139.93) (146.76)
Other line items

Show all line items

Columns are period end dates